Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study

Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study

Background: Immune checkpoint inhibitors (ICIs) have achieved promising effects in patients with non-small cell lung cancer (NSCLC). However, not all patients with NSCLC benefit from immunotherapy. There is an urgent need to explore biomarkers that could predict the survival outcomes and therapeutic...

Full description

Bibliographic Details
Main Authors:	Jia, J. (Author), Liu, C. (Author), Wang, X. (Author), Yan, Y. (Author)
Format:	Article
Language:	English
Published:	BioMed Central Ltd 2022
Subjects:	Biomarkers Immune checkpoint inhibitors (ICIs) Non-small cell lung cancer (NSCLC) Peripheral blood lymphocyte subsets
Online Access:	View Fulltext in Publisher

Similar Items

Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment
by: Tong III J, et al.
Published: (2021-05-01)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
by: Yongfeng Wu, et al.
Published: (2020-04-01)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
by: Wolfgang M. Brueckl, et al.
Published: (2020-12-01)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
by: Lu Meng, et al.
Published: (2021-09-01)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
by: Alex Friedlaender, et al.
Published: (2020-02-01)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with <i>ALK</i> Rearrangement
by: Yuko Oya, et al.
Published: (2020-04-01)

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
by: Eulalia Rodríguez-Martín, et al.
Published: (2020-08-01)

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
by: Anqi Lin, et al.
Published: (2021-09-01)

Circulating Lymphocyte Subsets  in Patients with Lung Cancer and Their Prognostic Value
by: Jun LUO, et al.
Published: (2011-08-01)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
by: Ye Li, et al.
Published: (2020-06-01)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
by: Ting Zhang, et al.
Published: (2021-06-01)

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
by: Diem S, et al.
Published: (2018-11-01)

Advance in Drug Resistance Mechanism of Immune Checkpoint Inhibitors
by: ZHANG Lanlan, et al.
Published: (2020-08-01)

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
by: Xinqing Lin, et al.
Published: (2021-07-01)

Early variations in lymphocytes and T lymphocyte subsets are associated with radiation pneumonitis in lung cancer patients and experimental mice received thoracic irradiation
by: Pu Zhou, et al.
Published: (2020-05-01)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
by: Zhenbin Qiu, et al.
Published: (2019-08-01)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
by: Yipeng Song, et al.
Published: (2021-02-01)

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
by: Qiao Yang, et al.
Published: (2021-04-01)

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
by: Brigida Anna Maiorano, et al.
Published: (2021-09-01)

Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer
by: Lova Sun, MD, et al.
Published: (2019-12-01)

Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case–Control Study
by: Kiriu T, et al.
Published: (2019-12-01)

Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response
by: Emily F. Goode, et al.
Published: (2021-05-01)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
by: Ho Jung An, et al.
Published: (2021-08-01)

Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports
by: Meng H. Tan, et al.
Published: (2019-01-01)

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
by: Aiben Huang, et al.
Published: (2021-05-01)

Clinical Significance of T Lymphocyte Subset Changes After First Line Chemotherapy in Peripheral Blood from Patients with Advanced Stage Adenocarcinoma Cell Lung Cancer
by: Xiang YAN, et al.
Published: (2012-03-01)

The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study
by: Jason C. Hsu, et al.
Published: (2021-07-01)

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
by: Jialin Qu, et al.
Published: (2020-07-01)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
by: Donghui Wang, et al.
Published: (2021-03-01)

Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy
by: Chen Hu, et al.
Published: (2021-09-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis
by: Manlio Mencoboni, et al.
Published: (2021-03-01)

Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors
by: Angelo Castello, et al.
Published: (2021-03-01)

Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: A real-world experience from a tertiary cancer center
by: Akhil Kapoor, et al.
Published: (2019-01-01)

The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
by: Xilin Hu, et al.
Published: (2021-10-01)

Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy
by: Sara Baglivo, et al.
Published: (2021-06-01)

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
by: Dantong Sun, et al.
Published: (2020-08-01)

Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in  Non-small Cell Lung Cancer
by: Peng WANG, et al.
Published: (2021-07-01)

If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for <i>KRAS</i>-Mutant Lung Cancer
by: Jens Köhler, et al.
Published: (2021-03-01)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
by: Maria A Papadaki, et al.
Published: (2020-06-01)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. H. Loosen, et al.
Published: (2021-03-01)

Cannot write session to /tmp/vufind_sessions/sess_uuub27oid5iv7um1v47ls96bng